Abstract | BACKGROUND: PROCEDURES:
Sorafenib was evaluated against the PPTP in vitro panel using 96-hr exposure at concentrations ranging from 1.0 nM to 10.0 µM. It was tested against the PPTP in vivo panels at a dose of 60 mg/kg administered by oral gavage daily for 5 days per week, repeated for 6 weeks. RESULTS: In vitro sorafenib demonstrated cytotoxic activity, with a median IC(50) value of 4.3 µM. Twenty of 23 cell lines had IC(50) values between 1.0 and 10.0 µM. A single cell line (Kasumi-1) with an activating KIT mutation had an IC(50) value < 1.0 µM (IC(50) = 0.02 µM). In vivo sorafenib induced significant differences in event-free survival (EFS) distribution compared to control in 27 of 36 (75%) of the evaluable solid tumor xenografts and in 1 of 8 (12.5%) of the evaluable ALL xenografts. Sorafenib induced tumor growth inhibition meeting criteria for intermediate activity (EFS T/C) in 15 of 34 (44%) evaluable solid tumor xenografts. No xenografts achieved an objective response. CONCLUSIONS: The primary in vitro activity of sorafenib was noted at concentrations above 1 µM, with the exception of a more sensitive cell line with an activating KIT mutation. The primary in vivo effect for sorafenib was tumor growth inhibition, which was observed across multiple histotypes.
|
Authors | Stephen T Keir, John M Maris, Richard Lock, E Anders Kolb, Richard Gorlick, Hernan Carol, Christopher L Morton, C Patrick Reynolds, Min H Kang, Amy Watkins, Peter J Houghton, Malcolm A Smith |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 55
Issue 6
Pg. 1126-33
(Dec 01 2010)
ISSN: 1545-5017 [Electronic] United States |
PMID | 20672370
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Benzenesulfonates
- Phenylurea Compounds
- Protein Kinase Inhibitors
- Pyridines
- Niacinamide
- Sorafenib
- Receptors, Vascular Endothelial Growth Factor
|
Topics |
- Animals
- Benzenesulfonates
(therapeutic use)
- Cell Line, Tumor
- Child
- Female
- Humans
- Mice
- Mice, Inbred BALB C
- Mice, Inbred NOD
- Mice, Nude
- Mice, SCID
- Neoplasms
(drug therapy, enzymology, pathology)
- Niacinamide
(analogs & derivatives)
- Phenylurea Compounds
- Protein Kinase Inhibitors
(therapeutic use)
- Pyridines
(therapeutic use)
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors)
- Sorafenib
- Xenograft Model Antitumor Assays
|